Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Recent developments in the treatment of peripheral T-cell lymphoma

Recent developments in the treatment of peripheral T-cell lymphoma Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of lymphatic neoplasms, which originate from mature (post-thymic) T-cells. Although comprising less than 15% of all non-Hodgkin lymphomas (NHL) in adults in Western countries, T-cell lymphomas still pose a considerable clinical challenge. To date, no standard therapy is available for the treatment of these T-cell malignancies. Treatment options that brought about substantial clinical progress in B-cell lymphomas perform only very poorly when used for T-cell lymphomas. With standard chemotherapy such as CHOP approximately 30% of T-cell lymphomas show a primary refractory course and only 35% of patients survive after 3–5 years. Therefore, novel treatment approaches need to be designed and validated in clinical trials. Here we discuss recent data including those presented at the last annual meeting of the American Society of Haematology (ASH 2009). Currently under investigation are new treatment modalities such as immune modulatory drugs, antifolates or histone deacetylase inhibitors. In addition, we present the ongoing trials that incorporate these new modalities. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Recent developments in the treatment of peripheral T-cell lymphoma

Loading next page...
 
/lp/springer-journals/recent-developments-in-the-treatment-of-peripheral-t-cell-lymphoma-Ye5Rxe36yO

References (20)

Publisher
Springer Journals
Copyright
Copyright © 2010 by Springer
Subject
Medicine & Public Health; Medicine/Public Health, general ; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-010-0191-x
Publisher site
See Article on Publisher Site

Abstract

Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of lymphatic neoplasms, which originate from mature (post-thymic) T-cells. Although comprising less than 15% of all non-Hodgkin lymphomas (NHL) in adults in Western countries, T-cell lymphomas still pose a considerable clinical challenge. To date, no standard therapy is available for the treatment of these T-cell malignancies. Treatment options that brought about substantial clinical progress in B-cell lymphomas perform only very poorly when used for T-cell lymphomas. With standard chemotherapy such as CHOP approximately 30% of T-cell lymphomas show a primary refractory course and only 35% of patients survive after 3–5 years. Therefore, novel treatment approaches need to be designed and validated in clinical trials. Here we discuss recent data including those presented at the last annual meeting of the American Society of Haematology (ASH 2009). Currently under investigation are new treatment modalities such as immune modulatory drugs, antifolates or histone deacetylase inhibitors. In addition, we present the ongoing trials that incorporate these new modalities.

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Jun 18, 2010

There are no references for this article.